<DOC>
	<DOCNO>NCT00006080</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness fenretinide treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Fenretinide Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy fenretinide assess 6-month progression- free survival patient recurrent malignant glioma . II . Determine rate measurable clinical response , time progression , overall survival patient treated drug . III . Determine unexpected toxicity drug patient . OUTLINE : This multicenter study . Patients stratify accord disease type ( glioblastoma multiforme ( close accrual 05/31/2001 ) gliosarcoma ( close accrual 05/31/2001 ) v anaplastic astrocytoma , anaplastic oligodendroglioma , mixed malignant glioma ) . Patients receive oral fenretinide twice daily week 1 4 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Quality life assess baseline course chemotherapy . Patients follow every 3 month . PROJECTED ACCRUAL : A total 41-85 patient ( 21-45 anaplastic astrocytoma , anaplastic oligodendroglioma , mixed malignant glioma 20-40 glioblastoma multiforme ( close accrual 05/31/2001 ) gliosarcoma ( close accrual 05/31/2001 ) ) accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial malignant primary glioma Glioblastoma multiforme ( close accrual 05/31/2001 ) Gliosarcoma ( close accrual 05/31/2001 ) Anaplastic astrocytoma Anaplastic oligodendroglioma Mixed malignant gliomas Original histological diagnosis lowgrade glioma allow subsequent histological diagnosis malignant glioma confirm Prior treatment 2 prior relapse allow Disease progression document least 2 prestudy brain scan Recent prior tumor resection recurrent progressive tumor allow recovered effect prior surgery PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 8 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( may transfusion dependent ) Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT le 2 time ULN Renal : Creatinine le 1.5 mg/dL Creatinine clearance least 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 month study Able swallow capsule No active infection No disease serious concurrent medical illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior interferon At least 1 week since prior thalidomide Chemotherapy : Recovered prior chemotherapy At least 4 week since prior cytotoxic therapy ( 2 week vincristine , 3 week procarbazine , 6 week nitrosoureas ) Endocrine therapy : At least 1 week since prior tamoxifen Prior steroid allow stable decrease dose least 57 day baseline MRI If steroid dose increase date baseline MRI initiation study drug , new baseline MRI require Radiotherapy : Not specify Surgery : See Disease Characteristics No concurrent surgery Other : At least 1 week since prior noncytotoxic agent ( e.g. , isotretinoin ) No concurrent anticancer therapy , include investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>